Enteritis F3: Acute enteritis or nephritis, jaundice, coronavirus diarrhea or Meniere's syndrome.

1. Acute enteritis: 125 patients took F3 or its modification and 105 cured (84 percent), six significantly improved (4.8 percent), four improved (3.2 percent) and 10 did not improve (8 percent).

2. Diarrhea: 121 patients were divided into a treatment group taking F3 (n=74) and a comparison group (n=47) taking antibiotics. Cured: 65 vs. 10 (87.9 vs. 21.2 percent); improved: 8 vs. 20 (10.8 vs. 42.2 percent); not improved: 1 vs. 17 (1.3 vs. 36.2 percent), P<0.01. The average treatment time was 3.5 days vs. 6 days.

3. Pediatric coronavirus diarrhea: Of 31 pediatric patients taking F3 for up to three days and all were significantly improved or cured. 60 infants were divided into a treatment group (n=25) taking F3 and a comparison group taking antibiotics (n=35). The average time to resume normal temperature was 1.18 vs. 2.82 days (P<0.001) while the time to stop diarrhea was 2.24 vs. 2.97 days (P<0.01).

4. Pediatric nephritis: 20 children took F3 or its modification and all were cured or significantly improved.

5. Meinere's syndrome: 32 patients were treated with F3 or its modification for up to two weeks found 28 were cured (87.50%) and four significantly improved (12.5 percent).

Toxicity and side effects: Patients may experience more sweating for a couple of days. Lab mice were feed twice a day at 25ml/Kg for seven days, which was equal to 583 times higher than the normal human dosage, and there was no death after seven days.